Literature DB >> 6458236

Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.

S Srinivasan, H C Neu.   

Abstract

The pharmacokinetics of moxalactam were determined in eight patients with end stage renal disease who were undergoing chronic hemodialysis. The mean half-life of moxalactam in the interdialysis period was 19 h, with a range of 9 to 30 h. The mean half-life of moxalactam during dialysis was 4 +/- 0.58 h. Serum levels of 30 +/- 10 micrograms/ml were present 24 h after a 1-g dose in the interdialysis period. A dose of 1 g at the end of each dialysis period in patients undergoing thrice-weekly hemodialysis would provide levels far in excess of the minimal inhibitory levels against Enterobacteriaceae.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6458236      PMCID: PMC181708          DOI: 10.1128/AAC.20.3.398

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Pharmacokinetics of cephalosporin antibiotics.

Authors:  J M Brogard; F Comte; M Pinget
Journal:  Antibiot Chemother (1971)       Date:  1978

2.  Pharmacokinetics of cefotaxime.

Authors:  K P Fu; P Aswapokee; I Ho; C Matthijssen; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.

Authors:  S Srinivasan; K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

4.  Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis.

Authors:  J Chodos; E L Francke; M Saltzman; H C Neu
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

5.  Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients.

Authors:  J P Fillastre; A Leroy; M Godin; G Oksenhendler; G Humbert
Journal:  J Antimicrob Chemother       Date:  1978-07       Impact factor: 5.790

6.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

7.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

8.  Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

Authors:  W K Bolton; W M Scheld; D A Spyker; T L Overby; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

9.  Pharmacokinetics of moxalactam in patients with renal insufficiency.

Authors:  M Lam; C V Manion; A W Czerwinski
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  9 in total
  3 in total

1.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

2.  The use of moxalactam in the treatment of serious infections due to multi-resistant organisms.

Authors:  S Srinivasan; E L Francke; C Ortiz-Neu; A S Prince; H C Neu
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

Review 3.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.